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Available online xxxxArchaea containmembrane lipids that differ from those found in the other domains of life (Eukarya and Bacteria).
These lipids consist of isoprenoid chains attached via ether bonds to the glycerol carbons at the sn-2,3 positions.
Two types of ether lipids are known, polar diether lipids and bipolar tetraether lipids. The inherent chemical sta-
bility and unique membrane-spanning characteristics of tetraether lipids render them interesting for oral drug
delivery purposes. Archaeal lipids form liposomes spontaneously (archaeosomes) and may be incorporated in
conventional liposomes (mixed vesicles). Both types of liposomes are promising to protect their drug cargo,
such as therapeutic peptides, against the acidic environment of the stomach and proteolytic degradation in the
intestine. They appear to withstand lipolytic enzymes and bile salts and may thus deliver orally administered
therapeutic peptides to distant sections of the intestine or to the colon, where they may be absorbed, eventually
by the help of absorption enhancers. Archaeal lipids and their semisynthetic derivativesmay thus serve as biolog-
ical source for the next generation oral drug delivery systems.
The aim of this review is to present a systematic overview over existing literature on archaea carrying diether and
tetraether lipids, lipid diversity, means of lipid extraction and puriﬁcation, preparation and in vitro stability stud-
ies of archaeal lipid-based liposomal drug carriers and in vivo proof-of concepts studies.







Stability1. Introduction & background
Despite tremendous research efforts undertaken in recent years, oral
delivery of labile drug compounds such as therapeutic proteins and pep-
tides still is challenging primarily for two reasons: 1) due to the harsh
environment of the lumen of the gastrointestinal (GI) tract, including
acidic pH and proteolytic enzymes, which the drug needs to withstand
and 2) the intestinal barrier, which the drug needs to come across on
its way to the site of action. The GI tract's physiological role is the diges-
tion of nutrients, including proteins and peptides, and subsequent ab-
sorption of digested fragments, including amino acids and short
peptides. To this end, the GI tract plays an important role in preventing5(6)-carboxyﬂuorescein; Chol,
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s.2016.12.036“foreign” compounds, including proteins and larger peptides, from en-
tering the body as these may be pathogenic or allergenic. These essen-
tial features of the GI tract account for the challenges encountered
with the oral administration of peptide drugs.
On the other hand, therapeutic peptides represent a rapidly growing
class within the pharmaceutical market with currently 60 US Food and
Drug Administration (FDA) approved peptide drugs and 140 and over
500 peptide drugs in clinical and preclinical trials, respectively
(Fosgerau and Hoffmann, 2015). The oral route in general is the pre-
ferred way of administration as it combines ease and convenience of
self-application with low production cost. However, routine oral appli-
cation of therapeutic peptides has been accomplished in only a few
cases (e.g. Desmopressin, Cyclosporin A) with a few more in various
phases of clinical trials. Despite major research efforts in recent years,
oral administration of peptide and protein drugs has not been accom-
plished for the vast majority of compounds to date (Renukuntla et al.,
2013). Clearly, novel andmore efﬁcient oral formulation strategies suit-
able for this class of compoundswould yield a tremendous step forward
in treatment options for a number of diseases where peptide based
drugs are essential.
Different formulation strategies, for example the use of absorption
enhancers, enzyme inhibitors, bioadhesive systems, site speciﬁc deliv-
ery systems and particulate carrier systems, such as liposomes or solid
lipid nanoparticles, have been investigated to enable the oral drugvery of therapeutic peptides, European Journal of Pharmaceutical Sci-
2 A.-C. Jacobsen et al. / European Journal of Pharmaceutical Sciences xxx (2017) xxx–xxxdelivery of peptide based drugs, for recent reviews see (Choonara et al.,
2014; Renukuntla et al., 2013) Varamini and Toth (2016); Gupta et al.
(2013).
Nanoparticulate carriers are regarded as promising for several rea-
sons: 1) theymayprotect their drug load against the harsh environment
of the upper intestine 2) theymay release their drug load in a sustained
or site speciﬁc manner (e.g. where the pH value is close to neutral and/
or the activity of proteolytic enzymes reduced) 3) they may slow down
the drug's passage along the GI tract and/or convey intimate contact
with the mucosa (e.g. through muco-adhesive surface characteristics).
We shall focus here on a speciﬁc type of nanoparticulate carrier,
liposomes.
Liposomes are (sub-)microscopic vesicular structures composed of
one or several phospholipid (PL) bilayer(s) enclosing an aqueous core.
Both, the aqueous core and the bilayer(s) can accommodate drug com-
pounds. Hydrophilic compounds like most peptidesmay be encapsulat-
ed and retained within the aqueous core for extended periods of time if
they are sufﬁciently large and charged, such that leakage across the bi-
layer(s) is slow. Hydrophobic compounds may be incorporated within
the bilayer(s) and their apparent solubility thus improved (Brandl,
2001). The general structure of liposomes is shown in Fig. 1.
Encapsulation of therapeutic peptides within liposomes may offer
some protection against the harsh environment in the GI tract. Thereby,
the premature degradation of the therapeutic compound can be
prevented. Recent studies support this by indicating that oral bioavail-
ability of poorly soluble and low bioavailable drugs could be enhanced
by liposome formulations (Fricker et al., 2010). Even though these re-
sults are promising, conventional liposomes only exhibit a limited sta-
bility at low pH in the presence of bile salts and lipases (Lasic, 1998),
thus demonstrating the clear need for an improvement of liposomal for-
mulations for oral use. Different strategies to stabilize liposomes in theFig. 1. General structure of liposomes. (A) ULV liposome, (B) MLV liposome, (C) Con
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of polymers such as polyethylene glycol (PEG), the sugar chain portion
of mucin or polyvinyl alcohol to the liposome surface (surface coating),
has a stabilizing effect on liposomal formulations (Silva et al., 2012). An-
other promising technique to increase liposomal stability, whichwill be
the focus of this review, is the use of archaeal membrane lipids in the
formulation of liposomes (Jacquemet et al., 2009).
Archaea are a diverse group of prokaryotic microorganisms. Even
though several archaeal specieswere already identiﬁed at the beginning
of the 20th century, (for a recent review see (Petitjean et al., 2015), ar-
chaea were not classiﬁed as a separate group of prokaryotes and were
initially called archaebacteria. With the introduction of a novel tech-
nique to reconstruct evolutionary relationships that is based on the
comparison of 16S ribosomal RNA (rRNA) sequences (Woese and Fox,
1977), archaea were found to be different from bacteria. Subsequently,
Woese and coworkers proposed the three domain model based on the
16S rRNA phylogeny, which divides the tree of life into three main do-
mains, Bacteria, Eukaryota and Archaea (Woese et al., 1990). With the
separation of Archaea into a distinct domain, the epithet “bacteria” be-
came redundant and hence literature uses the term Archaea instead of
archaebacteria today.
Originally, two major kingdoms (same as phyla in Bacteria) were
recognized for the domain Archaea, Euryarchaeota and Crenarchaeota.
The kingdom Euryarchaeota consists of cultivated species that are
methanogens, halophiles or thermophiles and is a phenotypically het-
erogeneous group. The kingdom Crenarchaeota is a more homogenous
group, mainly consisting of thermoacidophiles and thermophiles
(Woese et al., 1990). With the use of environmental molecular tech-
niques ‘non-extreme’ archaea (mainly mesophiles) were found in
manyenvironments, including the ocean, freshwater and soils. Research
concerning archaea is rapidly progressing and, besides mesophile Eury-ventional PL liposome, (D) Mixed vesicle and (E) Tetraether lipid archaeosome.
very of therapeutic peptides, European Journal of Pharmaceutical Sci-
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Nanoarchaeota, Thaumarchaeota and Aigarchaeota were discovered
and deﬁned (Villanueva et al., 2014). An overview over phylogenetic re-
lationships is given in Fig. 2.
Many archaeal species can withstand adverse conditions found in
extreme environments including high temperatures (thermophiles
and hyperthermophiles), high pressures (barophiles), high salt concen-
trations (halophiles) and low or high pH (acidophiles and alkaliphiles,
respectively). Among other factors, their unique membrane lipids that
are not generally seen in bacteria and eukaryotes are regarded as one
key adaption making archaea able to survive in these extreme environ-
ments (Konings et al., 2002). Two major groups of archaeal membrane
lipids are known diphytanylglycerol diether lipids (DELs) and its deriv-
atives, which are also called “archaeol”, as well as the dimeric
dibiphytanylglycerol tetraether lipids (TELs) and its derivatives, which
are also called “caldarchaeol” and “nonitolcaldarchaeol” respectively
(Kates et al., 1993) (see Fig. 3).
Archaeal membrane lipids are attracting considerable attention due
to their speciﬁc characteristics. Their stability may be utilized in bio-
technological or pharmaceutical applications. As stated earlier, the sta-
bilization of liposomes against the harsh environment of the GI tract is
one possible pharmaceutical application. However, archaea produce
various membrane lipids and still it is not fully understood which lipid
characteristics are most important when archaeal membrane lipids
are used in this context.
In this review structural features of archaeal membrane lipids and
their relation to different archaeal species, different lipid extraction
techniques and liposome preparation methods will be discussed. Final-
ly, results from both in vitro and in vivo studies investigating the stabil-
ity and performance of liposomes containing archaeal membrane lipids
will be summarized and discussed.Fig. 2. Phylogenic tree based on 16S rRNA showing the three kingdoms Crenarchaeota, Thaumar
both hyperthermophilic and mesophilic or only of mesophilic archaeal species, respectively. T
(red). Scale bar represents phylogenetic distance. (For interpretation of the references to color
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between liposomes consisting entirely of archaeal membrane lipids
from natural as well as synthetic origin, which will be termed
archaeosomes, conventional liposomes consisting entirely of PLs and
cholesterol (Chol) and liposomes partly consisting of PLs and archaeal
membrane lipids, which will be termed mixed vesicles (see Fig. 1.).
Furthermore, it has to be mentioned that archaeosomes and mixed
vesicles have been studied extensively in the context of vaccination
and gene delivery. As these potential applications focus on different fea-
tures of archaeal lipids, these will not be further discussed here.
2. Method
A computer-based literature search was conducted using the search
engines/databases Scopus® and SciFinder®. Different search strategies
were tested to cover the topic in a comprehensivemanner. Search strat-
egies and corresponding results are presented below.
Regardless of the database, in which a searchwas conducted, a com-
bination of the following keywords was used.
2.1. Liposome, archaeosome, archaea, oral drug-delivery, pharmaceutical
formulation, tetraether lipids, stability
A search in Scopus®was based on searching for separate keywords,
as Scopus® has a function, which lets you search for additional key-
words within the results. Using this function, results were narrowed
down to more speciﬁc results matching the topic of this review.
As vaccination and gene-delivery will not be discussed here, re-
sults dealing with vaccination and gene-delivery were excluded
using an additional feature of Scopus®, which lets you exclude cer-
tain keywords from the results. Excluded keywords includedchaeota and Euryarchaeota. The colors, red, orange and blue represent hyperthermophilic,
he dots show whether the membrane lipids are tetraether lipids (green) or diether lipids
in this ﬁgure legend, the reader is referred to the web version of this article.)
very of therapeutic peptides, European Journal of Pharmaceutical Sci-
Fig. 3. Examples of structures of both DELs and TELs, (A) DGD, dialkyl-glycerol-diether, (B) GDD, glycerol-dialkanol-diether (C) GDGT, glycerol-dialkyl-glycerol-tetraether (D) GDNT,
glycerol-dialkyl-glycerol-tetraether (E) Macrocyclic DGD.
(From Jensen 2015; with permission)
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munity”, “immune response”, “cellular immunity”, “gene-deliv-
ery”, “gene therapy” and “gene transfer”. Furthermore, keywords
related to dermal and transdermal drug-delivery were excluded as
well. Excluded keywords included “skin”, “skin absorption”,
“skin permeability”, “transcutaneous” and “keratinocytes”.
From the articles obtained by this procedure, the most relevant hits
were selected for further evaluation. Articles were selected from the
ﬁrst 25 results sorted by relevance. Furthermore, the article had to be
cited at least 10 times and/or had to be from 2015 to be selected for fur-
ther evaluation.
In contrast, a search in SciFinder® was initiated with searching for a
whole sentence. Results for the initial search were grouped according
concepts. For a given combination of concepts, potentially two groups
of results were created one where concepts are “closely associated
with one another” and one where concepts “were present anywhere
in the reference”. To obtain results matching the topic of this review,
only groups containing three or more concepts from the original search
were chosen. Additionally, the groups' concepts had to be “closely asso-
ciated with one another” and contain the keyword “archaea”,
“archaeosome” or “tetraether lipid” to exclude studies only investi-
gating conventional liposomes. SciFinder® has a function, which lets
you analyze results by “index terms”. Obtained results were analyzed
by the index terms “Drug-delivery systems” and “Pharmaceutical li-
posomes”. Furthermore, results dealing with vaccination, gene-deliv-
ery, dermal and transdermal drug-delivery were excluded manually.
Finally, articles with available full text cited 10 or more times and/or
all articles from 2015 and later were selected.
In total four searches were performed in the database SciFinder®.
The four searches were based on the sentences: “Liposomes contain-
ing lipids from archaea in pharmaceutical formulations for oralPlease cite this article as: Jacobsen, A.-C., et al., Archaeal lipids in oral deli
ences (2017), http://dx.doi.org/10.1016/j.ejps.2016.12.036administration”, “Archaeosomes for oral drug-delivery”, “Lipo-
somes containing tetraether lipids for oral drug-delivery” and “Sta-
bility of liposomes containing lipids from archaea”.
For a higher degree of comprehensibility, a search based on author
names identiﬁed from the searches in the databases Scopus® and
SciFinder® was conducted. For this purpose, the database Scopus®
was used.
An overview and summary of all identiﬁed articles, including origi-
nal research articles and reviews, sorted by date of publication is given
in Table in supplementary material.
3. Results & discussion
This section is divided into four subsections dealing with archaeal
membrane lipids in general, methods for extraction of archaeal mem-
brane lipids, methods for the preparation of liposomes and results of
in vitro and in vivo studies.
3.1. Archaeal membrane lipids: lipid structure and variability of lipids
Here we present a general description of archaeal membrane lipids,
especially with emphasis on structural features. Additionally, we will
discuss how different growth conditions can inﬂuence structural fea-
tures in various archaea.
Archaealmembrane lipids generally are composed of an C20–C40 iso-
prenoid core (phytanyl) linked to either glycerol and/or nonitol, which
can be substituted or unsubstituted with polar or non-polar head
groups (Hanford and Peeples, 2002). In contrast to membrane lipids
found in bacteria and eukaryotes, which have a sn-1,2 stereochemistry,
archaeal membrane lipids possess a sn-2,3 stereochemistry (Hanford
and Peeples, 2002). As stated before, two major groups of archaealvery of therapeutic peptides, European Journal of Pharmaceutical Sci-
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dimeric, bipolar TELs (De Rosa and Gambacorta, 1988; Hanford and
Peeples, 2002). DELs can vary in chain length, stereochemistry, head
group and/or the nature of the polyol. Furthermore, macrocyclic DELs
(see Fig. 2) have been discovered (De Rosa and Gambacorta, 1988).
Similar to conventional PL membranes, DELs membranes are arranged
in bilayers (Hanford and Peeples, 2002). Bipolar TELs are macrocyclic
in nature and generally divided into two classes, glycerol-dialkyl-glycer-
ol-tetraethers (GDGT) and glycerol-dialkyl-nonitol-tetraethers (GDNT)
(Jacquemet et al., 2009). Furthermore, the lipid core of TELs can contain
up to four cyclopentane rings per isoprene chain (Hanford and Peeples,
2002). TELs can vary in chain length, stereochemistry, head groups and/
or the number of cyclopentane rings in the lipid core. In contrast to PLs
and DELs, TELs tend to self-arrange in monolayers (Hanford and
Peeples, 2002) butmay also be incorporatedwithin PL and/or DEL bilay-
ers. Fig. 2 shows examples of archaeal lipid structures.
Themembrane lipid composition and lipid characteristics vary both,
within and among archaeal species and seem to be related to their hab-
itat. Lipid characteristics that often are regarded to varywith the habitat
are the TEL-to-DEL ratio and the degree of cyclization of the TEL lipid
core.
The membrane of halophiles mainly consists of DELs while those of
methanogens consist of 50–100% DELs and 0–50% TELs (Chong, 2010).
TELs make up the majority (90–95%) of the membrane lipids of
thermoacidophiles and hyperthermophilic neutrophiles (Chong,
2010). Studies by D. Lai et al. (2008) and G. D. Sprott et al. (1991)
have shown that the TEL-to-DEL ratio of different archaea is related to
the culturing temperature. For example, the membrane of
Methanococcus jannaschii grown at 50 °C consisted of 60% DELs, 22%
TELs and 18% macrocyclic DELs. At 75 °C its membrane consisted of
47% TELs, 36% macrocyclic DELs and 17% DELs (Sprott et al., 1991). Fur-
thermore, the TEL-to-DEL ratio of Archaeoglobus fulgidus increased from
0.3 ± 0.1 at 70 °C to 0.9 ± 0.1 at 89 °C (Lai et al., 2008). In the same
study, it could be shown that the number of cyclopentane rings in the
lipid core also seems to be related to the culturing temperature, as the
number of TELs from A. fulgidus grown at 70 °C showed less cyclization
than TELs from A. fulgidus grown at higher temperatures (Lai et al.,
2008). Identical conclusions could be drawn from other studies
(Chong, 2010). For example, H. Shimada and Co-workers were able to
show that the average number of cyclopentane rings in the polar lipid
fraction from Thermoplasma acidophilum increased from 3.6 at 45 °C to
4.5 at 60 °C, thereby supporting results from an earlier study by I. Uda
et al. (Shimada et al., 2008; Uda et al., 2001). A more recent study by
S. M. Jensen et al., which investigated the lipid composition of Sulfolobus
islandicus and Sulfolobus tokodaiimembranes at different temperatures
and growth phases, further supported the correlation between growth
temperature and number of cyclopentane rings in the lipid core. The re-
sults showed that for both species in all biological replicates the number
of cyclopentane rings increased with increasing growth temperature.
Furthermore, S.M. Jensen et al. could show that as an additional factor
growth phase seemed to have an inﬂuence on the number of
cyclopentane rings in the lipid core. For bulk lipids of both S. islandicus
and S. tokodaii the number of cyclopentane rings decreased from lag
to exponential phase and increased from exponential to stationary
phase again (Jensen et al., 2015b).
Additional environmental factors as for example salinity, pressure,
nutrients and pH, may have an inﬂuence on lipid characteristics (Oger
and Cario, 2013). However, these are not as extensively studied as tem-
perature. Considering the effect of pH, it was shown that the number of
cyclopentane rings in the total polar lipid fraction from Pyrococcus
horikoshii, which optimally grows at 95 °C and pH 6–8, is lower than
that from Sulfolobus acidocaldarius, which optimally grows at 70–75 °C
and pH 2 (Chong, 2010), indicating that pH indeed may have an inﬂu-
ence on the degree of cyclization. However contradicting results were
achieved when studying the effect of pH on cyclization (Jensen et al.,
2015b). For example, the number of cyclopentane rings inPlease cite this article as: Jacobsen, A.-C., et al., Archaeal lipids in oral deli
ences (2017), http://dx.doi.org/10.1016/j.ejps.2016.12.036T. acidophilum surprisingly decreased when pH was decreased
(Shimada et al., 2008).
3.2. Extraction of lipids from archaea and preparation of liposomes
3.2.1. Extraction of archaeal lipids
A key requirement for using archaeal lipids in liposome formulations
is the extraction of the lipids from the archaeal cell (biomass). Not only
the efﬁciency at which the lipids can be extracted (yield) but also the
lipid composition, i.e. whether certain lipids are preferentially extract-
ed, may be of importance for the usefulness of the gained extracts.
Extraction separates the desired compound(s) from a matrix e.g.
other compounds present in the mixture. Most lipid extraction proce-
dures take advantage of the fact that lipids are highly soluble in non-
polar solvents, when compared with other biomolecules (e.g. proteins,
nucleic acids and sugars), inorganic salts and other contaminating com-
pounds. Thus, lipids are often extracted by various forms of organic sol-
vent extractions. Another factor of variation is whether and how the
archaeal cells are disrupted prior to extraction.
3.2.2. Cell disruption
Prior to the actual lipid extraction, the cell samples are commonly
disrupted to facilitate the transfer of lipids from cells to organic solvents.
Common methods for cell disruption are sonication (Sturt et al., 2004)
homogenization (Harrison, 1991), exposure to solvents or heat
(Huguet et al., 2010). Cells which have a sturdy protein-based cell
wall require a more effective cell disruption/homogenization process
compared to soft tissues (Folch et al., 1957). Archaeal cell samples are
composed of a single cell membrane often coated with an S-layer. In
the ﬁeld of biotechnology, a common cell disruption method is bead-
beating/milling, where the mechanism is based on mechanical disrup-
tion with glass or metal beads (also called ball milling). Apart from con-
ventional ball mills, this can be obtained by using Dual asymmetric
centrifugation (DAC). Hereby, the combination of two centrifugal forces
gives vigorous agitation of a mixture of cells and beads (Massing et al.,
2008). DAC has been introduced by Jensen et al. for the disruption of ar-
chaeal cells (Jensen et al., 2015a).
3.2.3. Lipid extraction process
Several extraction protocols exist and the choice depends on the ob-
jectives. The requirements for an optimal archaeal lipid extraction are:
1) The lipids should preferentially be extracted in intact form, i.e. no
loss of polar head groups should occur.
2) The extraction yield should be high, i.e., extraction should be
efﬁcient.
3) The resulting lipid extract should be free of contaminating
compounds.
4) The extraction protocol should secure extraction of the most rele-
vant type of lipid (typically TELs) at good efﬁciency.
If the aim is to obtain a highly puriﬁed fraction of lipid withminimal
contamination, the tradeoff is typically reduced recovery, i.e. some of
the material will probably be lost during the extraction process. On
the other hand, a highly efﬁcient extraction method will likely extract
other compounds soluble in organic solvents, such as residues from
the media, which will affect the subsequent use of the lipid extract.
Therefore, it is necessary to ﬁnd a balance between these two require-
ments. With the amount of lipid being around 8–10% of dry archaeal
cell weight it is important to have an efﬁcient extraction method (De
Rosa et al., 1980; Lo et al., 1989; Nishihara and Koga, 1987).
Lipid extraction protocols can be divided into two groups 1) solvent
extraction (e.g. liquid-liquid extraction or Soxhlet extraction) or 2) solid
phase extraction. Selected extraction methods will be described below
with a particular emphasis on methods applied for the extraction of ar-
chaeal lipids. Since solid phase extraction has not been applied to ar-
chaeal lipids, hence it will not be discussed further here.very of therapeutic peptides, European Journal of Pharmaceutical Sci-
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The principle of liquid-liquid extraction is to transfer the desired
compound(s) from a matrix to typically an organic solvent in which
the target compounds are soluble. Often liquid-liquid extractions com-
prise two steps, ﬁrst a monophasic system, where a speciﬁc ratio of sol-
vents is used to obtain a miscible system. This is followed by a second
step where the ratio of the solvents is changed to induce phase
separation.
The “classical” method for the extraction of lipids according Bligh
and Dyer (B&D) in 1959 (Bligh and Dyer, 1959) is by the use of a
blendof chloroform (CHCl3):Methanol (CH3OH):water (H2O) as solvent
blend, which matches the solubility of a variety of lipid classes. In this
method the lipids areﬁrst extracted from the biomaterial by organic sol-
vents and then separated from contaminating compounds (e.g. protein,
sugars, nucleic acids and salt) by partition. This is carried out by mixing
the homogenized cells with speciﬁc CHCl3:CH3OH-ratios creating amis-
cible (monophasic) system.
B&Duse a ratio of 1:2:0.8 (CHCl3:CH3OH:H2O, v/v) during extraction
and then a ratio of 2:2:1.8 (CHCl3:CH3OH:H2O, v/v) to induce
partitioning (Bligh and Dyer, 1959). Since the 1960's many modiﬁca-
tions have been suggested for the B&Dprotocol to optimize themethod.
The H2O content has been replaced with 5% trichloroacetic acid for the
extraction of archaeal lipids, described as the modiﬁed Bligh and Dyer
(M-B&D), increasing the yield from 0.98% to 5.58% lipid content of dry
cells weight (Nishihara and Koga, 1987). Another variation was applied
to the M-B&D protocol by replacing the 5% trichloroacetic (TCA) with
phosphate buffered saline (PBS) and sonication of the extract (Sturt et
al., 2004). The reason for using PBS instead of TCA-buffer was not fur-
ther discussed in the paper. However, for extracting TELs the author rec-
ommended that TCA should be used in the last two steps of the
extraction.
3.2.5. Soxhlet extraction
Another example of a solvent extraction procedure for lipids is a
Soxhlet extraction. The principle of Soxhlet is lixiviation, i.e. separation
of soluble material from a solid sample with solvents by continuous
reﬂuxing (Luque de Castro and García-Ayuso, 1998). The sample is
placed in a sleeve within a reservoir. During operation the solvent is
heated and it evaporates to rise up to the condenser to be condensed
and drop down into the reservoirwith the sample. The reservoir is grad-
ually ﬁlled with solvent and when the liquid reaches the overﬂow level
it will ﬂow through the siphon back to the distillation ﬂask. Since there
is dripping freshly distilled solvent into the reservoir, analytes that are
soluble in the solvent are transferred from the solid matrix to the liquid
and the operation may be continued until complete extraction is
achieved (Luque de Castro and García-Ayuso, 1998).
The Soxhlet method has been applied as a preliminary step before
M-B&D extraction for the extraction of lipids from S. acidocaldarius (Lo
et al., 1989) and used as a separate method for the extraction of lipids
(Huguet et al., 2010). The yield of lipids was similar to the M-B&D
(9.5% compared to 9.1% of dry cell weight (Lo et al., 1989)), indicating
that the Soxhlet method here does not provide an improvement in
yield for the extraction of lipids from archaeal samples.
To determine the best protocols to extract archaeal lipids, two pa-
pers compared 3 and 13 extraction protocols, respectively (Huguet et
al., 2010; Lengger et al., 2012). According to Huguet et al., the best ex-
traction method was Soxhlet, when the purpose was to obtain intact
polar lipids from cultures (Huguet et al., 2010). This was mainly due
to the fact that the very polar intact lipids were difﬁcult to recover
from the aqueous phase in the M-B&D method. By using Soxhlet this
step was avoided. In contrast, the study of Lengger et al., showed that
the M-B&D method is the preferred method for yielding intact polar
lipids from environmental samples because Soxhlet extractions showed
a bias for certain lipid species, (Lengger et al., 2012).
Obviously, it depends on the desired application, which extraction
method to choose. However, to obtain intact polar lipids any acidPlease cite this article as: Jacobsen, A.-C., et al., Archaeal lipids in oral deli
ences (2017), http://dx.doi.org/10.1016/j.ejps.2016.12.036hydrolysis step should be avoided as this will result in a loss of the
head groups (Huguet et al., 2010).
3.2.6. Liposome preparation
Generally, liposomes including archaeosomes and mixed vesicles
were prepared by lipid hydration followed by ﬁlter extrusion giving
unilamellar vesicles (ULV), or bath sonication giving multilamellar
vesicles (MLV) (Benvegnu et al., 2005a; Parmentier et al., 2011a;
Parmentier et al., 2011b; Patel et al., 2000). For a protocol using sequen-
tial ﬁlter extrusion see (Jensen et al., 2015a), with factors of importance
for the outcome of ﬁlter extrusion are described in (Hinna et al., 2016).
In a recent study liposomeswere prepared by dual asymmetric centrifu-
gation (Parmentier et al., 2014).
3.3. In vitro stability screening of liposomes containing archaeal lipids in-
cluding archaeosomes and mixed vesicles
As stated earlier, the stability of liposomal formulations in the pres-
ence of certain stress factors including low pH, bile salts and lipases is
limited. Liposomal formulations containing archaeal lipids generally
show increased stability compared to conventional liposomes. Howev-
er, the stabilizing effect varies. In this section results from different in
vitro studies investigating the stability of liposomal formulations con-
taining archaeal lipids in the presence of stress factors including low
pH, bile salts and lipases are discussed (see Table 1). For comprehensi-
bility, Table 1 only shows excerpts of the presented studies.
To investigate liposomal stability in vitro, liposomes loaded with a
marker (14C-sucrose, 5(6)-carboxyﬂuorescein (CF) and ﬂuorescein iso-
thiocyanate (FITC)-dextran) are used as described in Section 3.2. Non-
encapsulated marker was removed from the prepared liposomes by
centrifugation, ultracentrifugation, Sephadex®G75 column chromatog-
raphy or size exclusion chromatography (Benvegnu et al., 2005a; Jensen
et al., 2015a; Li et al., 2010; Parmentier et al., 2011a; Patel et al., 2000).
Experiments normally are conducted at 37 °C. After the incubation of
the liposomal formulation in the presence of a stress factor, the amount
of releasedmarker is determined. Since CF and FITC-dextran are ﬂuores-
cent compounds, the amount of released CF or FICT-dextran will be de-
termined using a ﬂuorometer (Benvegnu et al., 2005a; Parmentier et al.,
2011a; Patel et al., 2000). One drawback of the method is that the ﬂuo-
rescence of CF is pH sensitive (Benvegnu et al., 2005a), complicating the
stability investigation at low pH. To avoid pH inﬂuencing the results, pH
can be increased to 7.4 after incubation using a saline NaOH buffer with
a pH of 11.9 (Benvegnu et al., 2005a) or a Tris buffer with pH 10
(Parmentier et al., 2011a), respectively. In the study by G.B. Patel et al.,
this challenge was bypassed by using radioactive 14C-sucrose. The
amount of released 14C-sucrose was determined by measuring radioac-
tive decay using a liquid scintillation counter (Patel et al., 2000).
As can be seen from the results presented by G.B. Patel (2000), MLV
liposomes generally aremore stable than ULV liposomes at low pH. Fur-
thermore, all formulations prepared fromM.mazei total polar lipid frac-
tion (TPL) were less stable at low pH than corresponding formulations
prepared from M. espanolae and T. acidophilum TPL. Comparing lipo-
somes prepared from M. espanolae and T. acidophilum TPL, liposomes
prepared from T. acidophilum TPL exhibit the greatest stability. MLV li-
posomes prepared from T. acidophilum TPL are the most stable, with a
leakage under 10% after 90 min. There are differences in membrane
lipid composition between the three investigated archaeal species.
The membrane of M. mazei consists entirely of archaeol and
hydroxyarchaeol lipids (DELs), in contrast the membrane of M.
espanolae and T. acidophilum contain caldarchaeol lipids (TELs), 65%
and 90% respectively (Patel et al., 2000). It could be seen that the stabil-
ity of liposomes prepared from TPL from the three different archaeal
species correlates with the content of TELs in the archaeal membrane.
In the study by T. Benvegnu et al. (2005b) the stability of liposomes
containing various synthetic TELs with identical core structure but with
different head groups were investigated. From the results it could bevery of therapeutic peptides, European Journal of Pharmaceutical Sci-
Table 1
Results from in vitro studies investigating the stability of archaeosomes and mixed liposomes in the presence of different stressors (low pH, bile salts and lipases).
Marker Formulation Stress factor Incub. time % leakage ref
14C-sucrose ULV archaeosomes fromMethanosarcina mazei TPL pH 2.0/2.5 90 min 100%/70% (A)
ULV archaeosomes from Methanobacterium espanolae TPL 60%/15%
ULV archaeosomes from Thermoplasma acidophilum TPL 35%/10%
MLV archaeosomes from Methanosarcina mazei TPL 90%/55%
MLV archaeosomes from Methanobacterium espanolae TPL 50%/10%
MLV archaeosomes from Thermoplasma acidophilum TPL 22%/b10%
CF ULV archaeosomes fromMethanosarcina mazei TPL Simulated human bile 2 min 100%
ULV archaeosomes from Methanobacterium espanolae TPL 60 min 90%
ULV archaeosomes from Thermoplasma acidophilum TPL 78%
MLV archaeosomes from Methanosarcina mazei TPL 84%
MLV archaeosomes from Methanobacterium espanolae TPL 78%
MLV archaeosomes from Thermoplasma acidophilum TPL 72%
CF MLV archaeosomes from Methanosarcina mazei TPL Pancreatic lipase
(3333 U/mL at pH 7.14)
60 min 19%
MLV archaeosomes from Methanobacterium espanolae TPL 19%
MLV archaeosomes from Thermoplasma acidophilum TPL 10%
ULV archaeosomes from Methanobacterium espanolae TPL 22%
ULV archaeosomes from Thermoplasma acidophilum TPL 10%
CF ULV archaeosomes from synthetic TELs with neutral head groups (hydroxyl or lactose) pH 2.0 5 min 100% (B)
ULV archaeosomes from synthetic TELs with phosphocholine head group b10%
CF ULV mixed liposomes from EPC and synthetic TELs with neutral head groups
(hydroxyl or lactose) (EPC:TEL 10:1)
0.4% sodium cholate 1 X
KBR buffer solution
1–2 min 60%
ULV mixed liposomes from EPC and synthetic TELs with neutral head groups
(hydroxyl or lactose) (EPC:TEL 10:3)
1–2 min 30%
ULV mixed liposomes from synthetic TELs with PC head group (various ratios) 1–2 min 100%
ULV archaeosomes from synthetic TELs with PC head group 1–2 min 100%
CF ULV mixed liposomes (EPC:GCTE:Chol 4:1:6), (EPC:GCTE:CS:Chol 4:1:1.2:4.8),
(EPC:GCTE:OT:Chol 4:1:1.2:4.8), (EPC:GCTE:TPGS:Chol 4:1:0.3:5.7)
pH 2.0 60 min 100% (C)
FITC-dextran ULV mixed liposomes (EPC:GCTE:Chol 4:1:6) pH 2.0 60 min 20%
ULV mixed liposomes (EPC:GCTE:CS:Chol 4:1:1.2:4.8) 0%
ULV mixed liposomes (EPC:GCTE:OT:Chol 4:1:1.2:4.8) 10%
ULV mixed liposomes (EPC:GCTE:TPGS:Chol 4:1:0.3:5.7) 0%
CF ULV mixed liposomes (EPC:GCTE:CS:Chol 4:1:1.2:4.8) Sodium taurocholate (10 mM) 60 min 30%
ULV mixed liposomes (EPC:GCTE:OT:Chol 4:1:1.2:4.8) 60%
ULV mixed liposomes (EPC:GCTE:TPGS:Chol 4:1:0.3:5.7) 60%
ULV mixed liposomes (EPC:GCTE:TPGS:Chol 4:1:0.3:5.7) 35%
FITC-dextran ULV mixed liposomes (EPC:GCTE:Chol 4:1:6) Sodium taurocholate (10 mM) 90 min 0%
ULV mixed liposomes (EPC:GCTE:CS:Chol 4:1:1.2:4.8) 0%
ULV mixed liposomes (EPC:GCTE:OT:Chol 4:1:1.2:4.8) 10%
ULV mixed liposomes (EPC:GCTE:TPGS:Chol 4:1:0.3:5.7) 15%
CF ULV mixed liposomes (EPC:GCTE:Chol 4:1:6) Pancreatin 0.3% × 8 USP 60 min 15%
ULV mixed liposomes (EPC:GCTE:CS:Chol 4:1:1.2:4.8),
(EPC:GCTE:OT:Chol 4:1:1.2:4.8), (EPC:GCTE:TPGS:Chol 4:1:0.3:5.7)
1–10%
FITC-dextran ULV mixed liposomes (EPC:GCTE:Chol 4:1:6) Pancreatin 0.3% × 8 USP 90 min 3%
ULV mixed liposomes (EPC:GCTE:CS:Chol 4:1:1.2:4.8),
(EPC:GCTE:OT:Chol 4:1:1.2:4.8), (EPC:GCTE:TPGS:Chol 4:1:0.3:5.7)
0%
(A) G.B. Patel et al. (2000), (B) T. Benvegnu et al. (C) J. Parmentier et al.
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membrane stabilizing properties of TELs but also the nature of the
head group. Synthetic TELswith neutral head groups (hydroxyl and lac-
tose) did not contribute to the stability of the liposomes at low pH com-
pared to conventional egg-phosphatidylcholine (EPC) liposomes in
contrast to synthetic TELs with an amphiphilic phosphocholine (PC)
head group, which increased liposome stability compared to the con-
ventional EPC liposomes. It has to be noticed that incubation time was
considerably shorter in this study compared to the other studies sum-
marized, making direct comparison difﬁcult.
In the study by J. Parmentier et al., the stability ofmixed vesicles con-
taining glycerylcaldityl tetraether (GCTE), PL, Chol and various
bioenhancers (cholylsarcosine (CS), octadecanethiol (OT) and TPGS
1000) was investigated. In contrast to the studies discussed earlier, no
stabilizing effect of TELs at low pH could be demonstrated compared
to the conventional liposome formulation (EPC:Chol 1:1) (Parmentier
et al., 2011a). Still, important conclusions can be drawn when compar-
ing the leakage of the low molecular weight marker CF and the larger
FITC-dextran. After 60 min of incubation 100% CF was released in con-
trast to only 12% FICT-dextran indicating that, small molecules are sub-
ject to considerably greater permeability than larger molecules. This
may seem favorable at ﬁrst glance, since peptides, which are large mol-
ecules, potentially can be delivered by this technology. Nevertheless, asPlease cite this article as: Jacobsen, A.-C., et al., Archaeal lipids in oral deli
ences (2017), http://dx.doi.org/10.1016/j.ejps.2016.12.036indicated by the results, the permeability for protons may be high and
may thus result in denaturation of the encapsulated peptides.
The investigation of archaeosome stability in the presence of simu-
lated human bile (SHB) presented in the study by G. Patel et al. shows
the same trends as seen for the stability of archaeosomes in low pH
(Patel et al., 2000). Generally, MLV archaeosomes are more stable than
ULV archaesomes, even though ULV and MLV archaeosomes from T.
acidophilum TPL showed very similar stabilities. Similar to low pH,
archaeosomes from M. mazei TPL were least stable compared to
archaeosomes fromM. espanolae and T. acidophilum and archaeosomes
from T. acidophilum TPL were comparably more stable than
archaesomes fromM. espanolae in the presence of bile salts. As stated
above, these results can be explained by considering the membrane
lipid composition i.e. archaeosome stability correlates with the content
of TELs in the membrane.
The stabilizing effect of the synthetic TELs investigated by T.
Benvegnu et al. were dependent on the nature of the head groups, sim-
ilarly to lowpH (Benvegnu et al., 2005b). TELswith amphiphilic PC head
groups did not contribute to the stability of the liposomes no matter in
which ratio they were used. In contrast, TELs with neutral head groups
(hydroxyl and lactose)were able to increase liposome stability. It is pos-
sible that the positive charge of the PC head groups contributes to an in-
creased interaction with the negatively charged sodium cholate,very of therapeutic peptides, European Journal of Pharmaceutical Sci-
8 A.-C. Jacobsen et al. / European Journal of Pharmaceutical Sciences xxx (2017) xxx–xxxtherebydestabilizing the liposomal formulation. The results from the in-
vestigation of liposome stability at low pH and in presence of bile salts
are inverted, making it difﬁcult to assess which formulation will be ad-
vantageous in an in-vivo situation, as the liposomal formulation would
meet both stress factors, low pH and bile salts, when used as an oral
formulation.
GCTE studied by J. Parmentier et al. is a TELwith neutral head groups
as are some of the synthetic TELs studied by T. Benvegnu et al., which
had a stabilizing effect on the liposomal formulation in the presence of
bile salts when compared to conventional EPC liposomes. The same is
true for mixed vesicles containing GCTE, which had an increased stabil-
ity in the presence of sodium taurocholate (10 mM) compared to lipo-
somes only containing Chol and EPC (1:1) (Parmentier et al., 2011a).
Furthermore, a remarkable stabilizing effect could be observed when
comparing mixed vesicles containing bioenhancers and GCTE to con-
ventional liposomes containing bioenhancers (85–90% CF and 40–65%
FICT-dextran release) (Parmentier et al., 2011a). This indicates a prom-
ising formulation strategy as a combined application of archaeal lipids,
increasing liposome stability, and bioenhancers, enhancing the uptake
of drug compounds, may effectively increase bioavailability in vivo
after oral administration of peptides.
Since both DELs and TELs contain ether bonds instead of ester bonds
as in PLs, a stabilizing effect against lipases of both DELs and TELs is ex-
pected, as lipases naturally cleave only ester bonds. Generally, all formu-
lations investigated by G.B. Patel et al. showed a good stability in the
presence of pancreatic lipase (Patel et al., 2000). Stability differences be-
tween the formulations from the different archaea were not as pro-
nounced as in the experiments at low pH and in the presence of bile
salts. However, archaeosomes from T. acidophilum still represent the
most stable formulation.
As for the formulations investigated by G.B. Patel et al., the mixed
vesicles studied by J. Parmentier et al. generally showed a good stability
against pancreatin. However, compared to the conventional liposome
formulation (EPC:Chol 1:1), no additional stabilizing effect of TELs in
the presence of pancreatin could be demonstrated, which may be due
to the content of PLs (36%) in the mixed vesicles (Parmentier et al.,
2011a).
3.4. In vivo investigation of liposomes containing archaeal lipids including
archaeosomes and mixed vesicles
Archaeal lipids have been found non-toxic upon administration by
both, the intraveneous and oral route (Omri et al., 2003). Parmentier
et al. (2011b) demonstrated that only a minute fraction of radiolabeled
lipid was absorbed after oral administration of archaeosomes.
In vivo studies investigating the performance of liposomal formula-
tions containing archaeal lipids in oral drug delivery were conducted by
Z. Li et al. (2010), J. Parmentier et al. (2011b, 2014) and P. Uhl et al.
(2016) and will be discussed in this section. Results for the best
performing formulations are summarized in Table 2.
Generally, the investigated mixed vesicles and archaeosomes were
prepared as described in Section 3.2. The formulations wereTable 2








Insulin – – – Mice Arch
Octreotide b0.3% 1.23% 4.1 Rats (♂) Mix
1.38% 4.6 Rats (♂) Mix
hGH 0.01% 3.37% 337 Wistar Rats (♂) Mix
Myrcludex B – – 3.5 Wistar Rats (♂) Mix
5 m
a AF-1 = A cationic semi-synthetic DGTE analog, (A) J. Parmentier (2011), (B) J. Parmentier
Please cite this article as: Jacobsen, A.-C., et al., Archaeal lipids in oral deli
ences (2017), http://dx.doi.org/10.1016/j.ejps.2016.12.036administered by oral gavage to male rats, male Wistar rats or mice
with induced diabetes, respectively (Li et al., 2010; Parmentier et al.,
2014; Parmentier et al., 2011b; Uhl et al., 2016).
In a study by Z. Li et al., archaeosomesmade from thepolar lipid frac-
tion E (PLFE) extracted from S. acidocaldarius as possible carriers for in-
sulin showed promising results. The glucose lowering effect of free
insulin administered orally was compared to that of insulin encapsulat-
ed in conventional liposomes and archaeosomes, respectively. As a con-
trol, insulin was given as an intraperitoneal injection.When insulin was
administered as free drug or encapsulated in conventional liposomes,
no glucose lowering effectwas observed. However, when insulin encap-
sulated in archaeosomes was administered a glucose lowering effect
was observed although itwasmoderate compared to the glucose lower-
ing effect induced by the intraperitoneal injection of insulin (Li et al.,
2010).
The effect of liposomal formulations containing TELs on the bioavail-
ability of the peptide drugs octreotide and human growth hormone
(hGH), respectively were investigated by J. Parmentier et al. in two sep-
arate studies (Parmentier et al., 2014; Parmentier et al., 2011b). An in-
crease in bioavailability could be demonstrated in both studies as
summarized in Table 2. A N4-fold increase in bioavailability of
octreotide could be observed for two mixed vesicle formulations com-
pared to free drug, indicating that themixed vesicles offer some protec-
tion frompremature degradation in theGI tract. Alsowhen compared to
the performance of conventional liposomes (EPC:Chol 2:1, 2.5 fold in-
crease in octreotide bioavailability), the mixed vesicles containing
TELs performed better indicating that TELs may increase the stability
of liposomes in the GI tract (Parmentier et al., 2011b). Still, it has to be
mentioned that not all mixed vesicle formulations did perform better
than the conventional liposome formulation (Parmentier et al.,
2011b). This may indicate the importance of the TEL-to-PL-ratio used
in a mixed vesicle formulation.
In the study investigating the bioavailability of hGH a 337-fold in-
crease in bioavailability could be observed compared to the free drug.
Here the experimental animals were pretreated with omeprazole, a
proton-pump inhibitor, leading to an increased gastric pH (Parmentier
et al., 2014). This may explain the larger increase in bioavailability com-
pared to the study investigating the bioavailability of octreotide because
low pH is an important stress factor for liposomal formulations as
discussed in Section 3.3. Additionally, cetylpyridinium chloride (CpCl)
was used as permeation enhancer (Parmentier et al., 2014), which
also is likely to play a role in the large increase in hGH bioavailability.
When considering thepotentially beneﬁcial effect of thepermeation en-
hancer CpCl and the pretreatment with omeprazole, contradictory re-
sults were achieved in a recent study by P. Uhl et al. (2016). Here the
performance of mixed vesicles containing GCTE for the oral administra-
tion of the investigational drug Myrcludex B was compared to conven-
tional liposomes and free drug. No signiﬁcant differences between the
performances of the formulation only containing GCTE, the GCTE for-
mulation after pretreatment with omeprazole or the formulation con-
taining additionally 1 or 10 mol% CpCl could be observed (Uhl et al.,
2016). It has to be mentioned that in the study by Parmentier et al.g archaeal lipids.a
ulation Enhancers Author
aeosomes from S. acidocaldarius PLFE – (C)
ed liposome (DPPC:GCTE 3:1) – (A)
ed liposome (DPPC:GCTE:AF-1 12:3:1) –
ed liposome (EPC:GCTE:Chol:CpCl 4:1:2.4:3.6) CpCl
Pretreatment: Omeprazole
(B)
ed liposome (EPC:Chol:GCTE) 10 mol% Chol,
ol% GCTE
– (D)
CpCl (1 mol% and 10 mol%)
Pretreatment: Omeprazole
(2014), (C) Z. Li (2010), (D) P. Uhl (2016).
very of therapeutic peptides, European Journal of Pharmaceutical Sci-
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same time in contrast to the study by P. Uhl (2016). So it cannot be
ruled out that a synergistic effect may have led to the signiﬁcant in-
crease in bioavailability. Similarly, the effect of permeation enhancers
and the pretreatmentwith omeprazolemay be drug compound speciﬁc.
Clearly, additional research is required to resolve this. Still, as seen in the
earlier studies, P. Uhl et al. could show that the performance of mixed
vesicles containing 5 or 10 mol% GCTE was signiﬁcantly better than
the performance of conventional liposomes. However, no signiﬁcant
difference between the 5 and 10mol% GCTEmixed vesicles could be ob-
served (Uhl et al., 2016). Additionally, P. Uhl et al. could show that long-
term storage of mixed vesicles containing GCTE is possible which was
achieved by freeze-drying (Uhl et al., 2016). For future research and
possibly the commercial application of archaeal lipids in pharmaceutical
formulations, this may be of great importance.4. Conclusion
New pharmaceutical formulation strategies for the oral administra-
tion of labile compounds are of great relevance, especially as more pro-
tein and peptide drugs are reaching themarket. Liposomal formulations
stabilized with archaeal lipids may potentially be used in this context
and hence different studies investigating archaeal lipids especially in
the context of pharmaceutical applications with emphasize one the
oral route of administration were reviewed.
In vitro studies discussed in this work generally showed that archae-
al membrane lipids were able to stabilize liposomal formulations. How-
ever, which structural feature(s) of archaeal membrane lipids primarily
are the cause for the stabilizing effect needs further investigation. For
example, the importance of the head group for the stabilizing effects
of archaeal membrane lipids remains unclear, even though the study
by T. Benvegnu et al. indicated that the head groups might have an im-
portant role (Benvegnu et al., 2005a). Nevertheless, it seems clear that
TELs, which arrange in a monolayer, have a signiﬁcantly larger stabiliz-
ing effect than DELs, as indicated by the study byG.B. Patel et al. Howev-
er, what the actual mechanism behind this observation is needs further
investigations for understanding the membrane physical effects
involved.
In vivo studies discussed in this work generally showed that liposo-
mal formulations containing archaeal lipids could increase the amount
of drug delivered orally compared to oral administration of the free
drug. This highly indicates the potential of this formulation for oral
administration.
In a study by J. Parmentier et al. (2011) a remarkable stabilizing ef-
fect of archaeal membrane lipids could be seen for liposomal formula-
tions containing permeation enhancers, which per se lead to increased
instability of liposomal formulations. Permeation enhancers represent
an attractive formulation possibility when considering the oral delivery
of therapeutic peptides as their application may lead to an increased
bioavailability. A combined application of archaeal lipids and perme-
ation enhancers may thus be of particular interest. However, in vivo
studies by J. Parmentier et al. (2014) and P. Uhl et al. (2016) showed
contradicting results, indicating that further work is needed on this
subject.
It appears advisable to combine liposomes with other mechanisms
for permeation enhancement to further improve absorption of peptides.
Liposomes containing archaeal lipids appear particularly promising in
this respect, as they may allow for delivery of protein/peptide drugs
and enhancers together within one construct to/near the enterocytes.
This may allow for a reduction of the amount of permeation enhancer
needed and thus side effects.
Overall it is clear that at the present stage the application of archaeal
lipids in the pharmaceutical and/or biotechnological industry would
need improvements in both the production and formulation of archaeal
lipids. When these will be implemented by future research andPlease cite this article as: Jacobsen, A.-C., et al., Archaeal lipids in oral deli
ences (2017), http://dx.doi.org/10.1016/j.ejps.2016.12.036development in this area then the application of archaeal lipids can
reach its already visible potential.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ejps.2016.12.036.References
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